| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
25,980,000 |
| Market
Cap: |
94.57(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.11 - $38 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
200 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,250 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
231,724 |
355,859 |
891,005 |
891,005 |
| Total Sell Value |
$811,485 |
$2,317,002 |
$14,925,115 |
$14,925,115 |
| Total People Sold |
1 |
4 |
11 |
11 |
| Total Sell Transactions |
13 |
20 |
57 |
57 |
| End Date |
2024-02-17 |
2023-11-16 |
2023-05-18 |
2022-05-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Szalay Aladar |
|
– – • |
2024-05-15 |
4 |
S |
$3.66 |
$62,624 |
I/I |
(17,094) |
1,139,821 |
|
- |
|
| Szalay Aladar |
|
– – • |
2024-05-14 |
4 |
S |
$3.58 |
$55,274 |
I/I |
(15,426) |
1,156,915 |
|
-2% |
|
| Szalay Aladar |
|
– – • |
2024-05-13 |
4 |
S |
$3.62 |
$12,478 |
I/I |
(3,446) |
1,172,341 |
|
-1% |
|
| Szalay Aladar |
|
– – • |
2024-05-08 |
4 |
S |
$3.82 |
$53,189 |
I/I |
(13,919) |
1,175,787 |
|
4% |
|
| Szalay Aladar |
|
– – • |
2024-05-07 |
4 |
S |
$3.67 |
$22,111 |
I/I |
(6,025) |
1,189,706 |
|
0% |
|
| Szalay Aladar |
|
– – • |
2024-05-01 |
4 |
S |
$3.30 |
$109,161 |
I/I |
(33,061) |
1,195,731 |
|
-11% |
|
| Szalay Aladar |
|
– – • |
2024-04-30 |
4 |
S |
$3.12 |
$63,981 |
I/I |
(20,535) |
1,228,792 |
|
-17% |
|
| Szalay Aladar |
|
– – • |
2024-04-29 |
4 |
S |
$3.25 |
$20,792 |
I/I |
(6,403) |
1,249,327 |
|
-15% |
|
| Szalay Aladar |
|
– – • |
2024-04-24 |
4 |
S |
$3.50 |
$28,251 |
I/I |
(8,064) |
1,255,730 |
|
-6% |
|
| Szalay Aladar |
|
– – • |
2024-04-23 |
4 |
S |
$3.49 |
$76,800 |
I/I |
(22,000) |
1,263,794 |
|
-5% |
|
| Szalay Aladar |
|
– – • |
2024-04-22 |
4 |
S |
$3.53 |
$50,597 |
I/I |
(14,331) |
1,285,794 |
|
-9% |
|
| Szalay Aladar |
|
– – • |
2024-04-17 |
4 |
S |
$3.71 |
$84,425 |
I/I |
(22,737) |
1,300,125 |
|
6% |
|
| Szalay Aladar |
|
– – • |
2024-04-16 |
4 |
S |
$3.53 |
$171,802 |
I/I |
(48,683) |
1,322,862 |
|
-3% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-12-15 |
4 |
S |
$12.94 |
$428,180 |
D/D |
(32,535) |
0 |
|
75% |
|
| Thomas John |
Director |
– • – |
2023-12-13 |
4 |
S |
$13.23 |
$120,387 |
D/D |
(9,000) |
463,460 |
|
76% |
|
| Tyree James L |
Director |
– • – |
2023-12-13 |
4 |
S |
$12.91 |
$118,969 |
D/D |
(9,000) |
3,460 |
|
76% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-12-07 |
4 |
S |
$11.85 |
$435,995 |
D/D |
(36,800) |
32,535 |
|
66% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-11-21 |
4 |
S |
$10.26 |
$191,555 |
D/D |
(18,665) |
69,335 |
|
53% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-11-20 |
4 |
S |
$11.26 |
$164,261 |
D/D |
(14,594) |
88,000 |
|
51% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-11-17 |
4 |
S |
$13.04 |
$46,170 |
D/D |
(3,541) |
102,594 |
|
56% |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-10-25 |
4 |
S |
$19.40 |
$110,638 |
I/I |
(5,704) |
1,371,545 |
|
64% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-10-24 |
4 |
AS |
$19.11 |
$99,351 |
D/D |
(5,200) |
106,135 |
|
-67% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-10-24 |
4 |
OE |
$6.00 |
$31,200 |
D/D |
5,200 |
111,335 |
|
- |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-10-23 |
4 |
S |
$19.97 |
$998,365 |
I/I |
(49,987) |
1,377,249 |
|
64% |
|
| Thomas John |
Director |
– • – |
2023-10-16 |
4 |
AS |
$20.50 |
$69,038 |
D/D |
(3,333) |
472,460 |
|
-60% |
|
91 Records found
|
|
Page 1 of 4 |
|
|
0.06 (1.68%) 
